5 Nephrology Headlines You Missed in October 2025

October delivered a slew of significant developments in nephrology, underscoring rapid momentum in both therapeutic innovation and clinical guidance. The month was highlighted by a landmark US Food and Drug Administration (FDA) approval in lupus nephritis for obinutuzumab, accompanied by new phase 3 data in IgA nephropathy (IgAN), reinforcing continued progress toward more effective, individualized treatment.